Maher will replace James Osborne on the ACell Board of Directors. Mr. Osborne will continue to advise ACell as a consultant on the current medical device reimbursement landscape.
"I am enthusiastic about the opportunity to join the Board of a dynamic company like ACell that is focused on innovative, market-changing solutions in wound care and surgical soft tissue repair. As ACell continues to advance its product development, expand its body of clinical research, and cultivate a dynamic product portfolio, I look forward to sharing my experience and guidance to support the company's ongoing growth as it advances patient care," said Maher.
Maher has also held positions with Johnson & Johnson, Pfizer Hospital Products Groups, and the US Food and Drug Administration. She has a BA in Bacteriology from Ohio Wesleyan University and a JD from the University of Baltimore.
About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN. For more information, call 800-826-2926 or visit www.acell.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acell-inc-announces-addition-of-sally-maher-jd-to-board-of-directors-300353839.html
SOURCE ACell, Inc.